The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal
antibodies targeting GD2 have substantially improved outcomes for children with high-risk …

Achieving a cure for metastatic neuroblastoma remains a challenge despite sensitivity to
chemotherapy and radiotherapy. Most patients achieve remission, but a failure to eliminate …

In the development of novel immune therapies for high-risk cancers, one goal is to find tumor
targets that are not widely shared by normal cells. One such target is the surface …

Tumor-specific monoclonal antibodies (mAbs) have demonstrated efficacy in the clinic,
becoming an important approach for cancer immunotherapy. Due to its limited expression …

Macrophage phagocytosis of tumor cells mediated by CD47-specific blocking antibodies
has been proposed to be the major effector mechanism in xenograft models. Here, using …

The role of CD47—often expressed on tumor cells—as a'don't eat me'signal that inhibits
macrophage phagocytosis is well established. But new work reveals a major role for other …

Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in
normal tissues, making most subtypes unsuitable as targets for cancer therapy. However …

Ovarian cancer and triple-negative breast cancer are among the most lethal diseases
affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are …

The progression of pancreatic oncogenesis requires immune-suppressive inflammation in
cooperation with oncogenic mutations. However, the drivers of intratumoral immune …